A Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Status: Recruiting
Location: See all (10) locations...
Intervention Type: Genetic
Study Type: Observational
SUMMARY
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
⁃ Subjects who only meet all of the following criteria are eligible for this study:
• nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
• Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study
Locations
United States
Massachusetts
Ophthalmic Consultants of Boston
NOT_YET_RECRUITING
Boston
Texas
Retina Consultants of Texas
NOT_YET_RECRUITING
Katy
Virginia
Wagner Macula & Retina Center
NOT_YET_RECRUITING
Norfolk
Other Locations
China
Beijing Hospital
NOT_YET_RECRUITING
Beijing
Peking Union Medical College Hospital
RECRUITING
Beijing
Zhejiang Provincial People's Hospital
NOT_YET_RECRUITING
Hangzhou
The Second Hospital Of Anhui Medical University
NOT_YET_RECRUITING
Hefei
EYE & ENT Hospital of Fudan University
RECRUITING
Shanghai
Xinhua Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine
NOT_YET_RECRUITING
Shanghai
Eye Hospital, WMU (Zhejiang Eye Hospital)
NOT_YET_RECRUITING
Wenzhou
Contact Information
Primary
Yongqin Wang
yongqin.wang@skytx.com
+86 18616737445
Time Frame
Start Date: 2024-04-02
Estimated Completion Date: 2031-03
Participants
Target number of participants: 83
Treatments
Long-term Follow-Up of Participants exposed to SKG0106 Dose level 1
No investigational product will be administered in this study.
Long-term Follow-Up of Participants exposed to SKG0106 Dose level 2
No investigational product will be administered in this study.
Long-term Follow-Up of Participants exposed to SKG0106 Dose level 3
No investigational product will be administered in this study.
Related Therapeutic Areas
Sponsors
Leads: Skyline Therapeutics